X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (107) 107
female (88) 88
male (87) 87
middle aged (86) 86
index medicus (76) 76
adult (75) 75
aged (75) 75
hematology (64) 64
oncology (45) 45
treatment outcome (38) 38
adolescent (35) 35
chemotherapy (28) 28
prognosis (28) 28
survival (26) 26
disease-free survival (24) 24
therapy (24) 24
aged, 80 and over (23) 23
antineoplastic combined chemotherapy protocols - therapeutic use (23) 23
survival rate (23) 23
young adult (23) 23
multiple myeloma - drug therapy (21) 21
stem-cell transplantation (20) 20
bortezomib (19) 19
cancer (18) 18
prospective studies (18) 18
remission induction (18) 18
risk factors (17) 17
transplantation (17) 17
follow-up studies (16) 16
hematology, oncology and palliative medicine (16) 16
abridged index medicus (15) 15
care and treatment (15) 15
neoplasm staging (15) 15
retrospective studies (15) 15
elderly-patients (13) 13
multiple myeloma (13) 13
multiple myeloma - mortality (13) 13
survival analysis (13) 13
umcg approved (12) 12
antineoplastic agents - therapeutic use (11) 11
hematopoietic stem cell transplantation (11) 11
lenalidomide (11) 11
multiple myeloma - genetics (11) 11
radiotherapy (11) 11
thalidomide (11) 11
antineoplastic combined chemotherapy protocols - administration & dosage (10) 10
dexamethasone (10) 10
doxorubicin - administration & dosage (10) 10
plus dexamethasone (10) 10
time factors (10) 10
transplantation, autologous (10) 10
transplantation, homologous (10) 10
acute disease (9) 9
antineoplastic agents - administration & dosage (9) 9
antineoplastic agents - adverse effects (9) 9
clinical trials (9) 9
melphalan (9) 9
netherlands (9) 9
rituximab (9) 9
stem cell transplantation (9) 9
toxicity (9) 9
tumors (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
bevacizumab (8) 8
dexamethasone - administration & dosage (8) 8
interferon-alpha (8) 8
randomized-trial (8) 8
recurrence (8) 8
response criteria (8) 8
versus-host-disease (8) 8
vincristine - administration & dosage (8) 8
antineoplastic agents (7) 7
bone-marrow-transplantation (7) 7
chemotherapy plus rituximab (7) 7
chronic myelogenous leukemia (7) 7
combined modality therapy (7) 7
criteria (7) 7
cyclophosphamide - administration & dosage (7) 7
cytarabine (7) 7
drug administration schedule (7) 7
gene expression profiling (7) 7
imatinib (7) 7
lung neoplasms - pathology (7) 7
maintenance (7) 7
multiple myeloma - pathology (7) 7
non-hodgkins-lymphoma (7) 7
patient outcomes (7) 7
peripheral-blood (7) 7
stem cells (7) 7
surgery (7) 7
t-cells (7) 7
antimitotic agents (6) 6
autologous transplantation (6) 6
bone-marrow transplantation (6) 6
carcinoma, non-small-cell lung - pathology (6) 6
chromosome aberrations (6) 6
combination therapy (6) 6
cyclophosphamide (6) 6
dose-response relationship, drug (6) 6
efficacy (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Frontiers in Immunology, ISSN 1664-3224, 2019, Volume 10
HLA-mismatches in hematopoietic stem-cell transplantation are associated with an impaired overall survival (OS). The aim of this study is to explore whether... 
Journal Article
Blood, ISSN 0006-4971, 2017, Volume 130, Issue Suppl 1, pp. 397 LP - 397
BackgroundThe EMN02/HO95 trial is the largest multicenter, randomized, phase 3 study conducted in the novel agent era and aimed to prospectively compare... 
Journal Article
Neuro-Oncology, ISSN 1522-8517, 06/2017, Volume 19, Issue 6, pp. 853 - 861
Background. The current method for assessing progressive disease (PD) in glioblastoma is according to the Response Assessment in Neuro-Oncology (RANO)... 
recurrent glioblastoma | SURVIVAL | CRITERIA | volumetry | PLUS IRINOTECAN | RESPONSE ASSESSMENT | PHASE-II | PATTERNS | RANO | SINGLE-AGENT BEVACIZUMAB | bevacizumab | MALIGNANT GLIOMAS | HIGH-GRADE GLIOMAS | TUMOR SIZE
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 1209 - 1209
Abstract The value of allogeneic hematopoietic stem cell transplantation (alloHSCT) in the treatment of multiple myeloma (MM) patients continues to be debated.... 
Journal Article
Lancet Oncology, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 943 - 953
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 630 - 630
Abstract Background: Salvage chemoimmunotherapy, followed by high-dose therapy and autologous stem cell transplantation (ASCT) for responding patients, is... 
Journal Article
Blood, ISSN 0006-4971, 2012, Volume 120, Issue 21, pp. 333 - 333
Abstract 333 BackgroundCombinations of a proteasome inhibitor (PI) with an Imid plus dexamethason such as VRD or VTD have shown significant activity in newly... 
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 2118 - 2118
Abstract Background: Carfilzomib has significant activity in newly diagnosed Multiple Myeloma (MM). We present an update of a Phase 2 trial of dose-escalated... 
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 3332 - 3332
Abstract Background The randomised, open-label, phase III trial HOVON-50 was designed to evaluate the effect of thalidomide during induction and maintenance in... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2012, Volume 30, Issue 24, pp. 2946 - 2955
Journal Article
Journal Article
Blood, ISSN 0006-4971, 01/2012, Volume 119, Issue 4, pp. 940 - 948
Journal Article
Blood, ISSN 0006-4971, 11/2011, Volume 118, Issue 21, pp. 3345 - 3345
Abstract Abstract 3345 Background: Acute lymphoblastic leukemia (ALL) is frequently complicated by venous thromboembolism (VTE). The reported incidence varies... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.